Last reviewed · How we verify

NCT03341364

Acceptance and Commitment Based Group Therapy for Cancer Patients

Withdrawn NA Last updated 24 October 2023
What this trial tests

NA trial testing ACT-based group therapy in Cancer. Withdrawn.

Timeline
10 September 2020
Primary endpoint
31 December 2021
31 December 2022

Quick facts

Lead sponsorRegion Skane
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingnone
Primary purposetreatment
Start date10 September 2020
Primary completion31 December 2021
Estimated completion31 December 2022
Sites1 location across Sweden

Drugs / interventions tested

Conditions studied

Sponsor

Region Skane — full company profile →

Who can join

18 and older, any sex, with Cancer or Psychological Distress. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the preliminary effects of an Acceptance and Commitment (ACT)-based group therapy compared to individual ACT-therapy for adult cancer patients suffering from psychological distress. Half of the participants will receive ACT in a group setting, while the other half will receive individual ACT.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of ACT-based group therapy

Trials testing the same drug.

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Region Skane trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03341364.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing